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Atherosclerosis and ensuing cardiovascular disease are major causes of death with
insufficient treatment options. In search for pathomechanisms of atherosclerosis, we
investigated the impact of the B2 bradykinin receptor, Bdkrb2, on atherosclerotic
lesion formation, because to date it is not clear whether the B2 bradykinin
receptor is atheroprotective or atherogenic. As a model of atherosclerosis, we used
hypercholesterolemic ApoE-deficient (apolipoprotein E-deficient) mice, which develop
atherosclerotic lesions in the aorta with increasing age. The role of Bdkrb2 in
atherosclerosis was studied in ApoE-deficient mice, which were either Bdkrb2-deficient,
or had moderately increased aortic B2 bradykinin receptor protein levels induced by
transgenic BDKRB2 expression under control of the ubiquitous CMV promoter. We
found that Bdkrb2 deficiency led to a significantly decreased atherosclerotic plaque
area whereas transgenic BDKRB2 expression enhanced atherosclerotic lesion formation
in the aorta of ApoE-deficient mice at an age of 8 months. Concomitantly, the
aortic content of reactive oxygen species (ROS) was higher in BDKRB2-expressing
mice whereas Bdkrb2 deficiency decreased aortic ROS levels of ApoE-deficient mice.
In addition, aortic nitrate as a marker of nitric oxide activity and the endothelial
nitric oxide synthase (eNOS) co-factor, tetrahydrobiopterin (BH4) were reduced in
BDKRB2-expressing ApoE-deficient mice. The decreased aortic BH4 content could be
a consequence of increased ROS generation and down-regulated aortic expression of
the BH4-synthesizing enzyme, Gch1 (GTP cyclohydrolase 1). In agreement with a causal
involvement of decreased BH4 levels in the atherogenic function of BDKRB2, we found
that treatment with the BH4 analog, sapropterin, significantly retarded atherosclerotic
plaque formation in BDKRB2-expressing ApoE-deficient mice. Together our data show
that the B2 bradykinin receptor is atherogenic, and the atherosclerosis-promoting
function of BDKRB2 is partially caused by decreased aortic BH4 levels, which could
account for eNOS uncoupling and further enhancement of ROS generation.
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Perhal et al. BDKRB2 Enhances Atherosclerosis
INTRODUCTION
Atherosclerosis and cardiovascular disease are leading causes of
death worldwide (1, 2). The high morbidity and mortality of
atherosclerotic vascular disease is in part attributed to limited
treatment options (1, 2). Elucidation of pathomechanisms
with the identification of potential new targets to improve
the pharmacotherapy of atherosclerosis therefore is of great
interest (1–3). To study pathomechanisms of atherosclerosis,
hypercholesterolemic, apolipoprotein E (ApoE)-deficient mice
are often used as a model because these mice reproduce
major features of atherosclerotic vascular disease such as
hypercholesterolemia-induced atherosclerotic lesion formation
in the vascular system with increasing age (4–8).
In this study, we investigated the role of the B2 bradykinin
receptor (BDKRB2) in atherosclerotic lesion formation. To
date it is not known whether BDKRB2 is atheroprotective
or atherogenic. Due to the blood pressure-lowering and
nitric oxide- (NO)-generating activity, the B2 bradykinin
receptor is considered to exert cardioprotection (9, 10).
This cardioprotective potential of B2 bradykinin receptor
stimulation by the agonist bradykinin and related kinins
of the kinin-kallikrein system is exploited therapeutically
with ACE (angiotensin-converting enzyme) inhibitors. ACE
inhibition not only blunts the generation of the vasopressor
angiotensin II but also prevents the proteolytic degradation
of bradykinin (9, 10). The contribution of bradykinin to the
antihypertensive activity of ACE inhibitors is well-documented
in experimental models and patients (11, 12). On the other
hand, the atherosclerosis-decreasing potential of ACE-inhibition
is reportedly independent from bradykinin and B2 bradykinin
receptor stimulation (13). Moreover, bradykinin and related
kinins are pro-inflammatory peptides, and inflammation is an
established risk factor of atherosclerosis (14, 15). In addition,
beneficial B2 bradykinin receptor-stimulated nitric oxide (NO)
generation and vasodilation are impaired in atherosclerosis
(16). Hypercholesterolemia and atherosclerosis are known to
cause endothelial dysfunction with concomitant uncoupling of
endothelial nitric oxide synthase (eNOS), which then generates
atherosclerosis-promoting reactive oxygen species (ROS) instead
of atheroprotective NO (17–19).
In view of this scenario, we investigated the impact of the
B2 bradykinin receptor on atherosclerotic lesion development.
To study the role of the B2 bradykinin receptor (Bdkrb2) in
atherosclerosis, we used (i) ApoE–/– mice with endogenously
expressed Bdkrb2, (ii) ApoE–/– mice with Bdkrb2 deficiency,
and (iii) ApoE–/– mice with moderately increased transgenic
BDKRB2 expression level. We found that transgenic B2 receptor
expression enhanced atherosclerotic plaque formation in the
aorta of ApoE–/– mice whereas Bdkrb2 deficiency retarded the
development of atherosclerosis.
MATERIALS AND METHODS
Experimental Model of Atherosclerosis,
and Generation of Transgenic Mice
The study was performed with three groups of male mice, i.e.,
(i) apolipoprotein E-deficient (ApoE–/–) mice in B6 (C57Bl/6J)
background (4–8), (ii) double-deficient Bdkrb2–/–ApoE–/– mice
(B2–/–ApoE–/–), and (iii) ApoE–/– mice with transgenic
expression of BDKRB2 under control of the ubiquitous CMV
immediate-early promoter/enhancer (derived from plasmid
pcDNA3, Invitrogen AG - Thermo Fisher Scientific). Bdkrb2-
deficient mice in B6 background were obtained by backcross
breeding of Bdkrb2–/– mice (20) for ten generations into B6
background. Double-deficient, Bdkrb2–/– and ApoE–/– mice,
were subsequently generated by cross-breeding, and identified
by genotyping PCR. For transgenic expression of BDKRB2, the
BDKRB2 transgene (2 ng/µL) was injected into the pronucleus
of fertilized oocytes isolated from super-ovulated ApoE–/– mice
with B6 background followed by transfer of 2-cell embryos
into pseudo-pregnant CD-1 foster mice similarly as described
(21). After weaning at an age of 3–4 weeks, PCR genotyping
was performed with ear-punch biopsies. Founder mice of
the FO generation were identified with stable integration
of the transgenic DNA into the genomic mouse DNA and
used for further breeding. Due to the pathologic phenotype
in ApoE–/– background, Tg-CMVBDKRB2 (Tg-B2++) mice
with ApoE-deficiency only were used for phenotyping but
otherwise, the colony of Tg-CMVBDKRB2 mice was maintained
on the B6 background without ApoE-deficiency (C57BL/6-
Tg-(CMVBDKRB2)Sjaa; Janvier No. 181.281 ETH Zurich).
Phenotyping was determined with 8-month-old mice. Mice were
kept on a 12 h light/12 h dark cycle, had free access to food and
water, and were fed a standard rodent chow diet (Ain-93-based
diet without addition of tocopherol acetate) containing 7% fat
and 0.15% cholesterol. As indicated, 3-month-old mice received
sapropterin (10 mg/kg/d, in drinking water, freshly prepared,
every day) for 5 months. Treatment of Tg-B2++ApoE–/– mice
andApoE–/–mice with the ACE inhibitor, captopril (20mg/kg/d,
in drinking water, freshly prepared, every day) was started at
an age of 3 months and continued for 5 months until the
end of the observation period at 8 months. At the end of
the study, anesthetized mice (ketamine/xylazine 100 mg/10mg
per kg body-weight) were perfused intracardially with ice-cold,
sterile PBS, the aorta was rapidly dissected on ice and processed
for further analysis. All animal experiments were performed
according to NIH guidelines, and reviewed and approved by the
local committee on animal care and use (Cantonal Veterinary
office, Zurich).
Biochemical Assays and Aortic
Atherosclerotic Lesion Determination
The atherosclerotic lesion area was determined in the aorta
by quantitative image analysis of oil red O-stained aortas
opened longitudinally (7, 8). The area of the aortic intima
with pathologic intimal atherosclerotic lesions was determined
with hematoxylin-eosin-stained, aortic paraffin sections of the
aortic arch. The aortic content of BH4 was determined as
described (22). The content of reactive oxygen species (ROS)
was determined by quantitative fluorescence evaluation of
dihydroethidium- (DHE)-stained aortic cryosections (8, 23).
The aortic expression of Gch1 (GTP cyclohydrolase 1) was
assessed after reverse transcription ofmRNA into cDNA followed
by quantitative real-time qRT-PCR using a LightCycler 480
Instrument (Roche). For quantitative real-time qRT-PCR, total
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aortic RNA was isolated by the RNeasy Mini kit according to
the protocol of the manufacturer (Qiagen). RNA purity was
confirmed by an absorbance ratio A260/280 of∼2.0. The absence
of RNA degradation and RNA quality were further controlled by
the presence of bright bands of 18S and 28S ribosomal RNA in
denaturing RNA electrophoresis. RNA was reverse transcribed
into cDNA by the Transcriptor High Fidelity cDNA Synthesis Kit
and subjected to qRT-PCR using the LightCycler R© 480 System
with the LightCycler R© 480 SYBR Green I Master reaction mix
according to the protocol of the manufacturer (Roche Molecular
Systems). Primer sequences used for determination of Gch1
expression by qRT-PCR were as follows: Gch1 forward 5′-GCC
GCTTACTCGTCCATTCT-3′, and Gch1 reverse 5-CCACCG
CAATCTGTTTGGTG-3′. Specific amplification of the Gch1
fragment of 358 bp was controlled by agarose gel electrophoresis.
Total number of B2 bradykinin receptor binding sites was
determined with aortic smooth muscle cells in HEPES-buffered
DMEM (supplemented with 1% BSA, protease inhibitors and
enalaprilat) by saturation radioligand binding (for 2 h at 4◦C)
with increasing concentrations (0.1–10 nM) of [2,3-prolyl-3,4-
3H(N)]bradykinin (79-96 Ci/mmol; Perkin Elmer) in the absence
and presence of 10µM HOE140 to determine non-specific
binding. Likewise, the number AT1 receptor binding sites
was determined with Sar1,[125I]Tyr4,Ile8-angiotensin II (2200
Ci/mmol; Perkin Elmer) in the absence and presence of 10µM
losartan. Aortic vascular smooth muscle cells were isolated from
aortas of ApoE–/–, Bdkrb2–/–ApoE–/–, Tg-B2++ApoE–/– and
non-transgenic B6 control mice at an age of 6–10 days. For
vascular smooth muscle cell (VSMC) isolation, aortas from 10 to
15 mice were dissected. Aortas were endothelium-denuded and
minced with a scalpel followed by a washing step with HEPES-
buffered DMEM (supplemented with 1mM L-glutamine, 100
I.U./ml penicillin and 100µg/ml streptomycin) and digestion at
37◦C with collagenase (2 mg/ml of collagenase type 2) under
constant agitation with a magnetic stirrer. The first digestion
step was discarded and in subsequent steps, the enzyme solution
was exchanged every 5min. Cells were filtered through a nylon
mesh (pore size 40µm) and collected in DMEM supplemented
with 10% FCS. After the aortic tissue was digested, cell fractions
were pooled. Thereafter, cells were collected by centrifugation
(300 x g), plated on cell culture plates and cultured in DMEM
supplemented with 10% FCS as described (24). Total inositol
phosphates of aortic smooth muscle cells were determined as
described (25). The specific B2 bradykinin receptor-stimulated
signal is given and was determined by bradykinin stimulation
(100 nM) in the absence and presence of 10µM of the B2-
specific antagonist, HOE140. Aortic Gch1 protein contents
were determined by immunoblot detection with GCH1/Gch1-
specific antibody (GCH1 monoclonal antibody M01, clone
4A12, Cat. No. H00002643-M01, Abnova) similarly as detailed
previously (25). Aortic tissue nitrate content was determined
with a fluorometric assay kit according to the protocol of the
manufacturer (Cayman Chemical).
Statistical Analysis
All data are presented as mean ± s.d. Analysis of variance
followed by a Post-test as indicated was performed to determine
statistical significance between more than two groups. Statistical
significance was set at a p-value of < 0.05. Statistical evaluation
was performed with GraphPad PRISM 7.0.
RESULTS
Increased Number of Aortic B2 Bradykinin
Receptors in Tg-B2++ApoE–/– Mice
To investigate the role of the B2 bradykinin receptor in
atherosclerosis, we used hypercholesterolemic ApoE–/– mice
as an experimental model of atherosclerosis. These mice
develop atherosclerotic lesions in the vascular system and
the aorta with increasing age (4–8). In frame of our study,
we compared three groups of ApoE–/– mice with different
expression levels of the B2 bradykinin receptor, i.e., (i) ApoE–
/– mice in B6 (C57Bl/6J) background with endogenous Bdkrb2
expression level, (ii) ApoE–/– mice in B6 background, which
are deficient in the B2 bradykinin receptor gene, Bdkrb2–
/–ApoE-/ (B2–/–ApoE–/–), and (iii) ApoE–/– mice in B6
background with transgenic expression of BDKRB2 under
control of the ubiquitous CMV promoter, Tg-B2++ApoE–/–
mice (Figure 1A). Because the genetic background has a strong
influence on the atherosclerotic phenotype of ApoE–/– mice
(26), all groups of transgenic mice used in our study had
identical B6 background. To obtain Bdkrb2–/– mice with pure
B6 (C57Bl/6J) background, we performed 2 years of backcrossing
of Bdkrb2–/– mice into the B6 background for more than 10
generations. These Bdkrb2–/– mice with B6 background were
then used for cross-breeding with ApoE–/– mice, to finally
obtain homozygous mice, which were double-deficient in Bdkrb2
and ApoE (Bdkrb2–/– and ApoE–/–). To generate mice with
moderately increased BDKRB2 level, we generated BDKRB2-
transgenic mice in ApoE–/– background with expression of
BDKRB2 under control of the ubiquitous CMV promoter.
We used the CMV promoter, because the endogenous B2
bradykinin receptor is also ubiquitously expressed. Male
offspring of these three study groups of mice with different
expression levels of the B2 bradykinin receptor were used to
analyze the impact of this receptor on the pathogenesis of
atherosclerosis (Figure 1A).
We initially characterized the vascular B2 bradykinin receptor
content of study groups. B2 bradykinin receptor levels on
aortic vascular smooth muscle cells (VSMC) isolated from
different transgenic mouse lines were determined by radioligand
binding. Our data show that B2 bradykinin receptor levels
were moderately increased on VSMC of Tg-B2++ApoE–/–
mice compared to ApoE–/– mice, i.e., the total number of
B2 receptor bindings sites was 72.9 ± 10.5 fmol/mg on Tg-
B2++ApoE–/– VSMC compared to 43.7 ± 8.2 fmol/mg in
ApoE–/– mice with endogenous Bdkrb2 level and 44.1 ± 7.7
fmol/mg in non-transgenic B6 mice (Figure 1B). As a control,
the B2 bradykinin receptor was absent in VSMC from double-
deficient, B2–/–ApoE–/– mice (Figure 1B). In contrast to the B2
bradykinin receptor, numbers of angiotensin II AT1 receptor
binding sites were not significantly different between all study
groups (Figure 1B). Endogenously expressed and transgenic
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FIGURE 1 | Increased number of aortic B2 bradykinin receptors in
Tg-B2++ApoE–/– mice. (A) Overview of three study groups of ApoE–/– mice.
(B) B2 bradykinin receptor binding sites (upper) and angiotensin II AT1
receptor binding sites (lower) were determined with aortic vascular smooth
muscle cells isolated from three study groups of ApoE–/– mice and
non-transgenic B6 mice (mean ± s.d.; n = 6; ***p < 0.001 (B6 and ApoE–/–
vs. B2–/–ApoE–/– and Tg-B2++ApoE–/–); Tukey‘s test). (C) The specific B2
bradykinin receptor-stimulated increase in total inositol phosphate levels
(B2-stimul. IPs) was determined with aortic vascular smooth muscle cells
isolated from different study groups (±s.d.; n = 3 biological replicates; ***p <
0.001 (Tg-B2++ApoE–/–) vs. B6 and ApoE–/–; ***p < 0.001 (B2–/–ApoE–/–)
vs. B6, ApoE–/–, and Tg-B2++ApoE–/–; Tukey‘s test).
B2 bradykinin receptors of aortic smooth muscle cells were
functional and mediated an increase in total inositol phosphate
levels upon bradykinin stimulation (Figure 1C).
Together these data show that transgenic BDKRB2 expression
under control of the ubiquitous CMV promoter led to a
moderately increased number of B2 bradykinin receptor binding
sites on aortic smooth muscle cells of Tg-B2++ApoE–/– mice
whereas the B2 receptor was absent in B2–/–ApoE–/– mice with
deficiency of the B2 bradykinin receptor gene, Bdkrb2.
Transgenic BDKRB2 Expression Enhances
Atherosclerotic Lesion Formation Whereas
Bdkrb2 Deficiency Leads to a Decreased
Atherosclerotic Plaque Area in the Aorta of
ApoE–/– Mice
To investigate the impact of the B2 bradykinin receptor on
atheroma formation, we determined the atherosclerotic lesion
area in the aorta of 8-month-old ApoE–/– mice. As outlined
before, the study compared three different groups of mice, i.e.,
(i) ApoE–/– mice with endogenous Bdkrb2 expression level,
(ii) B2–/–ApoE–/– mice with Bdrkb2 deficiency, and (iii) Tg-
B2++ApoE–/– mice with moderately increased B2 receptor
level due to transgenic BDKRB2 expression. All mice had
B6 background. Atherosclerotic lesion area in the aorta was
quantified by oil red O staining (Figure 2A). We found that
transgenic BDKRB2 expression led to a significantly enhanced
atherosclerotic plaque formation in the aorta of Tg-B2++ApoE–
/– mice, i.e., the atherosclerotic lesion area was increased 2.2
± 0.4-fold in Tg-B2++ApoE–/– mice compared to ApoE–/–
mice with endogenous Bdkrb2 level (Figure 2B). In contrast, B2
bradykinin receptor deficiency led to a significantly decreased
atherosclerotic plaque area in double-deficient, B2–/–ApoE–/–
mice compared to ApoE–/– mice with endogenously expressed
Bdkrb2 (Figure 2B). These data provide strong evidence that
the B2 bradykinin receptor enhances the progression of
atherosclerotic plaque formation in the aorta of 8-month-old
ApoE–/– mice as an experimental model of atherosclerosis.
Transgenic BDKRB2 Expression Leads to
an Increased Aortic ROS Content in
Tg-B2++ApoE–/– Mice
Enhanced generation of reactive oxygen species (ROS) is
a major contributor to atherosclerotic plaque formation in
experimental models of atherosclerosis and involved in the
pathogenesis of atherosclerosis in patients (8, 18, 27). We
asked whether the B2 bradykinin receptor led to an increased
aortic ROS content of Tg-B2++ApoE–/– mice. Aortic ROS was
detected in situ by dihydroethidium (DHE) staining (8, 23).
Quantitative image analysis shows that the ROS production
in the aorta of BDKRB2-expressing Tg-B2++ApoE–/– mice
was significantly increased compared to ApoE–/– mice with
endogenous B2 receptor expression level, i.e., aortic ROS levels
of Tg-B2++ApoE–/– mice were 1.6 ± 0.3-fold higher than
those of ApoE–/– mice (Figures 3A,B). Vice versa, there was
a significant decrease in the aortic ROS content of double-
deficient B2–/–ApoE–/– mice compared to ApoE–/– mice with
intact Bdkrb2 gene (Figures 3A,B). Taken together, the B2
bradykinin receptor mediates an enhanced production of ROS
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FIGURE 2 | Transgenic BDKRB2 expression enhances atherosclerotic lesion
formation whereas Bdkrb2 deficiency leads to a decreased atherosclerotic
plaque area in the aorta of ApoE–/– mice. (A,B) Atherosclerotic lesion area
was determined with oil red O-stained aortas by quantitative image analysis.
Representative aortic images are shown in (A), and (B) shows quantitative
data evaluation (mean ± s.d.; n = 5; **p < 0.01 and ***p < 0.001 vs.
ApoE–/–; Dunnett‘s test).
in the aorta of atherosclerosis-prone Tg-B2++ApoE–/– mice
with hypercholesterolemia.
The Aortic Nitrate Content as a Marker of
NO Activity and the Nitric Oxide Synthase
(NOS) Cofactor Tetrahydrobiopterin (BH4)
Are Decreased in Tg-B2++ApoE–/– Mice
On vascular endothelial cells, the B2 bradykinin receptor is
known for its nitric oxide (NO)-stimulating function (10, 28, 29).
Nitric oxide is considered as a major atheroprotective factor
released from intact endothelium (30, 31). On the other hand,
cardiovascular risk factors such as hypercholesterolemia and
atherosclerosis trigger endothelial dysfunction (29, 30), which
leads to endothelial nitric oxide synthase (eNOS) uncoupling
(19). Uncoupled eNOS produces atherogenic superoxide instead
of atheroprotective NO (19). In agreement with previous data on
defective NO generation in hypercholesterolemic ApoE–/– mice
(32), the aortic tissue nitrate content as a marker of NO activity in
vivo (33), was significantly decreased in ApoE–/– mice compared
to non-transgenic B6 mice, i.e the aortic nitrate of ApoE–/–
mice was 539 ± 89 nmol/g compared to 1031 ± 158 nmol/g
in B6 mice (Figure 4A). Transgenic expression of BDKRB2
further decreased the aortic nitrate content in Tg-B2++ApoE–
/– mice compared to ApoE–/–mice with endogenous Bdkrb2
expression (Figure 4A). Vice versa, deficiency of Bdkrb2 led
FIGURE 3 | Transgenic BDKRB2 expression leads to an increased aortic ROS
content in Tg-B2++ApoE–/– mice. (A,B) The aortic ROS content was
determined by DHE staining of aortas from different study groups.
Representative images are shown in (A), and (B) shows quantitative data
(mean ± s.d.; n = 4; *p < 0.05 (ApoE–/–) and ***p < 0.001
(Tg-B2++ApoE–/–) vs. B6; **p < 0.01; other comparisons are indicated;
Tukey‘s test; bar: 100µm).
to a significantly increased aortic nitrate content of Bdkrb2–
/–ApoE–/– mice compared to ApoE–/– mice (Figure 4A). This
finding is complementary to previous data, which show that
deficiency of Bdkrb2 increases the serum nitrate level (34).
Nevertheless, the aortic nitrate content of Bdkrb2–/–ApoE–/–
mice was not normalized to B6 control level by B2 bradykinin
receptor deficiency (Figure 4A), most likely because defective
NO generation in atherosclerotic Bdkrb2–/–ApoE–/– mice has
additional causes, which are independent of Bdkrb2, e.g., ApoE
deficiency-induced hypercholesterolemia. Together these data
show that the B2 bradykinin receptor mediates a decrease in
aortic nitrate content as a marker of dysfunctional aortic (e)NOS
activity in Tg-B2++ApoE–/– mice whereas deficiency of Bdkrb2
increases the aortic nitrate level in Bdkrb2–/–ApoE–/– mice.
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FIGURE 4 | The aortic nitrate content as a marker of NO activity and the nitric oxide synthase (NOS) cofactor tetrahydrobiopterin (BH4) are decreased in
Tg-B2++ApoE–/–mice. (A,B) Aortic nitrate (A) and aortic BH4 (B) contents of study groups (mean ± s.d.; n = 5; *p < 0.05; **p < 0.01; ***p < 0.001 vs. ApoE–/– and
TgB2++ApoE–/– (A); mean ± s.d.; n = 4; *p < 0.05 vs. B6 and B2–/–ApoE–/–, and ***p < 0.001 vs. B6 (B); other comparisons are indicated; Tukey‘s test). (C,D)
Intimal atherosclerotic lesion area was determined on hematoxylin and eosin- (H&E)-stained paraffin sections of the aortic arch. Quantitative data evaluation is shown
in (C), and (D) shows representative sections (mean ± s.d.; n = 3; ***p < 0.001 vs. ApoE–/– and B2–/–ApoE–/–; other comparisons are indicated; Tukey‘s test).
The eNOS uncoupling during the pathogenesis of
atherosclerosis was partially attributed to down-regulation
of the (e)NOS cofactor, tetrahydrobiopterin, BH4 (35, 36). We
asked whether the decreased aortic nitrate content of BDKRB2-
transgenic Tg-B2++ApoE–/– mice was accompanied by changes
in aortic BH4 levels. We measured the aortic BH4 content and
found that transgenic BDKRB2 expression led to a decrease in
the aortic BH4 content of Tg-B2++ApoE–/– mice, which was
2.48 ± 0.56 pmol/mg in Tg-B2++ApoE–/– mice compared to
5.23 ± 1.09 pmol/mg in ApoE–/– mice with endogenous Bdkrb2
expression level (Figure 4B). For comparison, aortic BH4 levels
were not significantly different between ApoE–/– mice with
Bdkrb2-deficiency and non-transgenic B6 mice (Figure 4B). This
observation could be due to the fact that there are two opposing
mechanisms acting on the aortic BH4 level in Bdkrb2–/–ApoE–
/– mice, i.e., (i) ApoE deficiency, which decreases the aortic
BH4 content, and (ii) Bdkrb2 deficiency, which counteracts
the ApoE deficiency-induced BH4 decrease. The net result is a
normalization of aortic BH4 content in Bdkrb2–/–ApoE–/– mice
toward the level of non-transgenic B6 mice (Figure 4B).
Histologic evaluation of hematoxylin-eosin-stained aortic
specimens from the different groups of ApoE–/– mice confirmed
the enhanced atherosclerosis progression of Tg-B2++/ApoE–/–
mice by an increased intimal atherosclerotic lesion area in the
aortic arch of Tg-B2++ApoE–/– mice with transgenic BDKRB2
expression compared to ApoE–/– mice with endogenous
Bdkrb2 expression, and double-deficient B2–/–ApoE–/– mice
(Figures 4C,D). Together these data show a decrease in (e)NOS
activity as documented by a reduced aortic content of nitrate and
depletion of the (e)NOS co-factor, BH4, by the B2 bradykinin
receptor in hypercholesterolemic Tg-B2++ApoE–/– mice with
concomitantly enhanced atherosclerotic lesion development.
The Major BH4-Synthesizing Enzyme, Gch1
(GTP Cyclohydrolase 1) Is Down-Regulated
by BDKRB2 in Tg-B2++ApoE–/– Mice
We searched for the mechanism underlying the aortic decrease
in the (e)NOS cofactor, BH4, which was triggered by the B2
bradykinin receptor. BH4 deficiency in atherosclerosis could
be caused by at least two different mechanisms, i.e., by (i)
BH4 oxidation as a consequence of increased ROS levels (cf.
Figure 3), and (ii) impaired BH4 synthesis due to decreased
levels/activity of the GTP cyclohydrolase 1 (Gch1), which is the
rate-limiting enzyme in tetrahydrobiopterin (BH4) biosynthesis
(36, 37). Previous data have shown that endothelial Gch1 activity
and expression are decreased by various cardiovascular risk
factors (37). Therefore, we determined the aortic expression level
of Gch1 in Tg-B2++ApoE–/– mice. Our data show that aortic
Gch1 expression levels were significantly decreased in BDKRB2-
expressing Tg-B2++ApoE–/– mice compared to ApoE–/– mice
with endogenous Bdkrb2 levels, i.e., aortic Gch1 levels were 2.1-
fold lower in Tg-B2++ApoE–/–mice compared toApoE–/–mice
(Figure 5A). For comparison, the aortic Gch1 expression level of
B2–/–ApoE–/– mice with Bdkrb2 deficiency was not significantly
different from non-transgenic B6 mice (Figure 5A). As a control,
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FIGURE 5 | The major BH4-synthesizing enzyme, Gch1 is down-regulated by BDKRB2 in Tg-B2++ApoE–/– mice. (A) Aortic gene expression level of Gch1 was
quantified of indicated study groups (mean ± s.d.; n = 4; *p < 0.05 vs. B6; **p < 0.01; ***p < 0.001 vs. B6 and B2–/–ApoE–/–; other comparisons are indicated;
Tukey‘s test). (B) The aortic protein content of Gch1 was determined by immunoblot with Gch1-specific antibodies. The left panel shows immunoblot detection of
aortic Gch1 of indicated study groups, and the right panel shows quantitative data (mean ± s.d.; n = 6; *p < 0.05; ***p < 0.001 vs. ApoE–/– and B2–/–ApoE–/–;
other comparisons are indicated; Tukey‘s test).
immunoblot detection of the aortic Gch1 protein confirmed
the significant decrease of the aortic Gch1 content in BDKRB2-
expressing Tg-B2++ApoE–/– mice compared to ApoE–/– mice
with and without endogenously expressed Bdkrb2 (Figure 5B).
Treatment With the BH4 Analog,
Sapropterin, Retards Atherosclerotic
Plaque Formation and Decreases the
Aortic ROS Content of Tg-B2++ApoE–/–
Mice
Is there a causal relationship between decreased aortic BH4
levels and enhanced atherosclerotic plaque formation in
BDKRB2-expressing, Tg-B2++ApoE–/– mice? To address
this question, we treated Tg-B2++ApoE–/– mice with the
BH4 analog, sapropterin. Treatment outcome of 8-month-
old mice was evaluated after 5 months of treatment. Our
experiments show that BH4 supplementation retards the
enhanced atherosclerotic plaque formation of Tg-B2++ApoE–
/– mice (Figures 6A,B). In contrast, the effect of BH4 in
ApoE–/– mice with endogenously expressed Bdkrb2 was not
significant (Figure 6B). Concomitantly, supplementation
of BH4 also decreased the exaggerated aortic ROS content
of Tg-B2++ApoE–/– mice (Figures 6A,C). As a control,
saproterin treatment led to increased aortic BH4 levels in
Tg-B2++ApoE–/– mice and ApoE–/– mice with endogenous
Bdkrb2 levels (Figure 6D). These experiments show that BH4
supplementation is capable to counteract the atherosclerosis-
promoting ROS generation in Tg-B2++ApoE–/– mice with
transgenic BDKRB2 expression.
ACE Inhibition With Captopril Inhibits
Atherosclerotic Plaque Accumulation in
Tg-B2++ApoE–/– Mice
The angiotensin II AT1 receptor is a major contributor to
atherosclerosis-promoting ROS generation in ApoE–/– mice (8,
38–40). Atherogenic functions of the AT1 receptor are enhanced
by BDKRB2 (25, 41), and atherosclerosis-related endothelial
dysfunction can be prevented by inhibition of angiotensin II
AT1 receptor stimulation with an inhibitor of the angiotensin
II-generating ACE (42, 43). Because BDKRB2 enhanced the
endothelial dysfunction of Tg-B2++ApoE–/– mice, we asked
whether inhibition of ACE-dependent angiotensin II generation
in Tg-B2++ApoE–/– mice could retard the BDKRB2-enhanced
atherosclerosis progression. To address this question, we treated
Tg-B2++ApoE–/– mice with the ACE inhibitor, captopril
(20 mg/kg/d) for 5 months. Atherosclerotic lesion area was
evaluated of oil red O-stained aortas and revealed that captopril
largely prevented the accumulation of atherosclerotic plaques
in 8 month-old Tg-B2++ApoE–/– mice (Figures 7A,B). In
agreement with previous studies (7, 8), captopril also inhibited
the formation of atherosclerotic lesions in ApoE–/– control
mice with endogenous Bdkrb2 expression (Figures 7A,B).
Taken together, inhibition of ACE-dependent angiotensin II
AT1 receptor activation is capable to prevent the BDKRB2-
enhanced atherosclerotic lesion development in Tg-B2++ApoE–
/– mice. Consequently, the atherogenic function of the B2
bradykinin receptor in ApoE–/– mice involves a synergistic
interplay between the B2 bradykinin receptor and angiotensin
II-stimulated AT1 receptor activation.
DISCUSSION
In this study, we investigated the impact of the B2
bradykinin receptor on atherosclerotic lesion formation
in hypercholesterolemic ApoE–/– mice as a model of
atherosclerosis. We found that a moderately increased BDKRB2
level in Tg-B2++ApoE–/– mice led to a significantly enhanced
progression of atherosclerotic lesion development whereas
deficiency of Bdkrb2 retarded the accumulation of atherosclerotic
plaques in Bdkrb2–/–ApoE–/– mice.
In search for pathomechanisms underlying the enhanced
atherogenesis triggered by BDKRB2, we detected an increased
aortic ROS content in Tg-B2++ApoE–/– mice compared to
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FIGURE 6 | Treatment with the BH4 analog, sapropterin, retards
atherosclerotic plaque formation and decreases the aortic ROS content of
Tg-B2++ApoE–/– mice. (A–C) Enhanced atherosclerotic plaque formation of
Tg-B2++ApoE–/– mice is retarded, and aortic ROS content is decreased by
treatment with sapropterin. In (A), representative oil red O-stained aortas (left
panels) and DHE-stained aortic sections (right panels) from TgB2++ApoE–/–
mice are shown (bar: 100µm; right panels). Panels (B,C) present quantitative
data (mean ± s.d.; n = 4; ***p < 0.001 vs. all other groups of mice; Tukey‘s
test). (D) Aortic BH4 contents of study groups (mean ± s.d.; n = 4; ***p <
0.001 vs. BH4-treated mice; Tukey‘s test).
ApoE–/– mice with endogenous Bdkrb2 expression level. In
addition, the endogenous Bdkrb2 contributes to enhanced ROS
generation in ApoE–/– mice because the aortic ROS content
FIGURE 7 | ACE inhibition with captopril inhibits atherosclerotic plaque
accumulation in Tg-B2++ApoE–/– mice. (A,B). Atherosclerotic plaque area
was determined of 8 months-old Tg-B2++ApoE–/– and ApoE–/– mice after
treatment without and with the ACE-inhibitor (+ACE-I), captopril. Panels in (A)
show representative oil red O-stained aortas, and (B) shows quantitative data
(mean ± s.d.; n = 5; **p < 0.01 vs. ApoE–/–; ***p < 0.001 vs.
Tg-B2++ApoE–/–+ACE-I, ApoE–/– and ApoE–/–+ACE-I; Tukey‘s test).
was significantly lower in double-deficient Bdkrb2–/–ApoE–
/– mice compared to ApoE–/– mice with intact endogenous
Bdkrb2 gene. The increased vascular ROS level could directly
contribute to enhanced atherosclerotic lesion formation because
ROS is known to accelerate atherogenesis in animal models
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of atherosclerosis and patients with atherosclerotic vascular
disease (8, 18, 27). Aortic ROS generation in ApoE–/– mice
was previously attributed to the atherosclerosis-enhancing
function of the angiotensin II AT1 receptor, which generates
ROS by activation of NADPH oxidases (8, 38). Activation of
the AT1 receptor in experimental models of atherosclerosis
and patients with cardiovascular disease is increased due to
hypercholesterolemia-induced up-regulation of the systemic
renin angiotensin system (39, 40). Our study identifies the B2
bradykinin receptor as another player involved in enhanced ROS
generation in ApoE–/– mice. B2 bradykinin receptor-enhanced
ROS generation could as well be mediated by the AT1 receptor,
which becomes hyperactive by protein complex formation with
the B2 bradykinin receptor (25, 41). Notably, endogenous Bdkrb2
levels are sufficient to sensitize the AT1 receptor-stimulated
response, and the AT1-sensitizing function of the B2 bradykinin
receptor does not require bradykinin (25, 41). In agreement with
a bradykinin-independent function of the B2 bradykinin receptor
in atherosclerosis, treatment of ApoE–/– mice with the B2
bradykinin receptor-specific antagonist, HOE140, did not alter
atherosclerosis progression (13). However, the (brady)kinin-
generating kallikrein system was not active in this study, because
treatment with the B2-specific antagonist, HOE140, had no effect
on blood pressure, neither under basal conditions nor upon
blood pressure lowering with the ACE inhibitor, ramipril (13).
Thus, bradykinin-dependent and bradykinin-independent effects
need to be considered in the atherosclerosis-promoting activity of
the B2 bradykinin receptor depending on the activation state of
the kinin-kallikrein system.
As a consequence of the AT1-receptor sensitizing activity,
the B2 bradykinin receptor could mediate a decrease in the
nitric oxide synthase (NOS) cofactor, BH4, which is inactivated
by ROS (37). Decreased BH4 leads to uncoupled eNOS, which
in turn generates more ROS. The decrease in aortic BH4
content could synergistically be aggravated by downregulation
of Gch1, which is the rate-limiting enzyme in BH4 synthesis. In
concert with hypercholesterolemia, BDKRB2 and Bdkrb2 could
decrease vascular Gch1 expression and protein level by activation
of Gi-coupled signaling because hypercholesterolemia and Gi-
coupled signaling are both known to down-regulate Gch1 (44–
46). The ensuing depletion of vascular BH4 could contribute
to eNOS uncoupling in the pathogenesis of atherosclerosis
(35). The uncoupled eNOS generates detrimental ROS instead
of atheroprotective NO (Figure 8). Transgenic animal models
support that Gch1 deficiency and reduced vascular BH4
accelerate atherosclerosis whereas supplementation of BH4 or
Gch1 expression reverse these deficits and retard atherosclerosis
(19, 35, 47). In agreement with these findings, we found that
treatment with BH4 decreased aortic ROS levels and dampened
the atherosclerosis-enhancing effect of BDKRB2.
It is well-established that the bradykinin-potentiating effect
of ACE inhibitors contributes to cardio-protection [Figure 8A,
(9, 10)]. However, the atherosclerosis-lowering potential of ACE
inhibition does not necessarily rely on bradykinin-stimulated
Bdkrb2 activation, e.g., when there is no activation of the
(brady)kinin-generating kallikrein system (13). A B2-specific
antagonist, HOE140, also had no effect on atherosclerosis
FIGURE 8 | Scheme of physiologic and pathophysiologic functions of the B2
bradykinin receptor. (A,B) Physiologic functions of the B2 bradykinin receptor
in endothelial cells are atheroprotective (A), and pathophysiologic functions (B)
of the B2 bradykinin receptor in hypercholesterolemia enhance atherogenesis.
progression in ApoE–/– mice without ACE inhibition (13),
most likely because the beneficial NO-generating capacity of
endothelial B2 bradykinin receptor stimulation is impaired
in atherosclerosis and cardiovascular disease [Figure 8B, (42,
43, 48)]. Because atherosclerosis progression in ApoE–/– mice
is not affected by the B2-specific antagonist, HOE140 (13),
atherosclerosis promotion by Bdkrb2 in ApoE–/– mice could
largely be mediated by the angiotensin II AT1 receptor-
sensitizing function of Bdkrb2, which is bradykinin-independent
(25, 41). In agreement with this conclusion, our study shows that
inhibition of angiotensin II AT1 receptor stimulation by an ACE
inhibitor completely prevents atherosclerotic lesion formation in
Tg-B2++ApoE–/– mice. Thus, under hypercholesterolemia, the
B2 bradykinin receptor gene is atherogenic, leads to increased
vascular ROS, mediates a decrease in (e)NOS activity as
evidenced by a reduced aortic nitrate content, and enhances
aortic BH4 deficiency (Figure 8B). BH4 depletion contributes to
the atherogenic activity of the B2 bradykinin receptor because
supplementation with BH4 was sufficient to inhibit aortic ROS
and retard atherosclerosis progression triggered by transgenic
BDKRB2 expression (Figure 8B).
Enhanced ROS generation in hypercholesterolemia and
atherosclerosis is largely attributed to angiotensin II AT1 receptor
stimulation (8, 38). Consequently, inhibition of detrimental AT1
receptor-stimulated ROS generation by an ACE inhibitor or
AT1 antagonist in animal models and patients could exert a
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dual protective function regarding the atherogenic activity of
BDKRB2, i.e., (i) restoration of protective B2 bradykinin receptor
signaling, and (ii) neutralization of the AT1-sensitizing function
of BDKRB2. Symptoms of the herein deduced atherogenic
activity of the B2 bradykinin receptor can be prevented by
ACE inhibition, which inhibits sensitized AT1 receptor signaling,
blunts exaggerated ROS generation, and heals uncoupled eNOS
in atherosclerosis and cardiovascular disease (42, 43, 47).
Consequently, the agonist-stimulated B2 bradykinin receptor
could become anti-atherogenic upon treatment with an ACE
inhibitor, which prevents endothelial dysfunction triggered by
oxidized low-density lipoproteins in a B2 bradykinin receptor
stimulation-dependent manner (49).
Taken together, our study shows that the atherosclerosis-
enhancing function of the ubiquitously expressed B2 bradykinin
receptor involves a synergistic interplay between enhanced
ROS generation, dysfunctional NO activity and AT1 receptor
activation. Pathomechanisms identified in this study could
act in concert with already established B2 and/or AT1
receptor-dependent atherogenic activities. Notably, the following
mechanisms mediated by the B2 and/or AT1 receptor could
play a direct or indirect role in B2 bradykinin receptor-
enhanced atherosclerosis: (I) The B2 bradykinin receptor
could promote atherosclerosis by the reduced activation
of atheroprotective AT1-inhibitory receptors, AGTR2 and
MAS1 (34, 50–52), which are directly down-regulated by
the B2 bradykinin receptor and angiotensin II AT1 receptor
(34, 53) and indirectly dampened via angiotensin II AT1-
mediated ACE2 down-regulation (54). (II) In addition, the B2
bradykinin receptor could enhance atherogenesis by decreasing
the expression of the vasculoprotective endothelial Kruppel-like
factor 4, KLF4 (55), which is directly downregulated by
angiotensin II AT1 stimulation [(56); NCBI GEO dataset
GSE19286 in Abd Alla et al. (7)], and indirectly down-regulated
by reduced Mas receptor activation (57). (III) And finally, the B2
bradykinin receptor-stimulated atherogenesis could involve the
enhanced aortic infiltration with macrophages and inflammatory
immune cells, which is promoted by angiotensin II AT1 receptor
signaling directly (7, 58), and indirectly by B2 bradykinin and
angiotensin II AT1 receptor-mediated downregulation of Mas,
which accounts for a decreased expression of atheroprotective
sirtuin 1, SIRT1 (34, 57, 59). In view of this panoply of different
atherogenic functions, specific targeting of the detrimental B2
- AT1 receptor axis could be envisaged as a potential approach
to treat not only atherosclerosis but also related pro-thrombotic
activities triggered by the B2 bradykinin and angiotensin II AT1
receptors (34, 60, 61).
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